ARTICLE | Clinical News
Albireo's A3309 meets constipation endpoint
October 12, 2010 11:57 PM UTC
Albireo (Gothenburg, Sweden) said 10 and 15 mg once-daily oral A3309 for eight weeks met the primary endpoint in a Phase IIb trial to treat chronic idiopathic constipation. A3309 significantly increas...